Back

GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia

Vattathil, S. M.; Blostein, F.; Miller-Fleming, T. W.; Davis, L. K.; Alzheimer's Disease Genetics Consortium (ADGC), ; Alzheimer's Disease Neuroimaging Initiative, ; Wingo, T. S.; Wingo, A. P.

2025-02-02 psychiatry and clinical psychology
10.1101/2025.01.31.25321498 medRxiv
Show abstract

INTRODUCTIONNeuropsychiatric symptoms in dementia (NPS) collectively refer to behavioral and psychological symptoms affecting individuals with mild cognitive impairment (MCI) or Alzheimers disease or related dementia (ADRD). NPS are among the most troubling aspects of living with dementia and their treatments have limited efficacy. We aim to investigate genetic variants contributing to NPS to identify new therapeutic targets. METHODSWe performed a genome-wide association study (GWAS) for nine NPS domains measured by the NPI-Q in 12,800 participants of European ancestry with MCI or ADRD recruited by Alzheimers disease research centers across the U.S. RESULTSWe found genome-wide significant signals for agitation, anxiety, apathy, delusions, and hallucinations in the APOE locus that were driven by the APOE {varepsilon}4 allele. We replicated these findings in two independent datasets. Mediation analyses revealed that MCI/ADRD severity only partially mediated the GWAS signals, except for apathy. DISCUSSIONThese findings suggest the APOE {varepsilon}4 allele influences NPS independently of and beyond its effect on ADRD.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.